Edimer Pharmaceuticals, Inc.

Calculating rank

USPTO Granted Patents = 5

% Expired Patents = 20.0

CIPO Patents = 2

EPO Patents = 2

Forward Citations = 2

Loading Chart...

7 inventors (with patents filed for the assignee):

Pascal Schneider (5 out of 18 patents)

Christine Kowalczyk-Quintas (2 out of 3 patents)

Nathalie Dunkel (2 out of 2 patents)

4. Stéphane Demotz (2 out of 2 patents)

5. Neil Kirby (1 out of 2 patents)

6. Anh Thu Dang (1 out of 1 patent)

7. Christine Kowalczyk (1 out of 1 patent)

8. Stephane Demotz (0 patent)

5 patents: Sort by Forward Citations

1. 9925239 - Treatment of X-linked hypohidrotic ectodermal dysplasia with a fusion EDA1 protein (2018-03-27),

2. 9695245 - Anti-ectodysplasin antibodies (2017-07-04),

3. 9175085 - Treatment of X-linked hypohidrotic ectodermal dysplasia with ectodysplasin A agonist (2015-11-03),

4. 8741297 - Preparation of isolated agonist anti-EDAR monoclonal antibodies (2014-06-03),

5. 8496937 - Preparation of isolated agonist anti-EDAR monoclonal antibodies (2013-07-30),

Company Overview

Edimer Pharmaceuticals, Inc. is a biotechnology company focused on developing novel therapies for rare, genetic disorders. The company's lead product candidate is EDI200, a potential treatment for X-linked hypohidrotic ectodermal dysplasia, a rare genetic disorder that impacts sweat gland function. Edimer is dedicated to improving the lives of patients with rare diseases through innovative research and development.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

5 Patents

#33 in Andover, MA

#2,894 in Massachusetts

#51,644 in US

Andover, MA, United States of America

Edimer Pharmaceuticals, Inc.

Forward Citations = 2

7 inventors:

Pascal Schneider (5 out of 18 patents)

Christine Kowalczyk-Quintas (2 out of 3 patents)

Nathalie Dunkel (2 out of 2 patents)

4. Stéphane Demotz (2 out of 2 patents)

5. Neil Kirby (1 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Edimer Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/edimer-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

2 patents (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

2 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]